Brigatinib (AP26113) Efficacy and Safety in ALK plus NSCLC: Phase 1/2 Trial Results

被引：0
|
作者：
Gettinger, Scott N. [1 ]
Bazhenova, Lyudmila [2 ]
Salgia, Ravi [3 ]
Langer, Corey J. [4 ]
Gold, Kathryn A. [5 ]
Rosell, Rafael [6 ,7 ]
Shaw, Alice [8 ]
Weiss, Glen J. [9 ]
Dorer, David J. [10 ]
Rivera, Victor M. [10 ]
Conlan, Maureen G. [10 ]
Kerstein, David [10 ]
Camidge, Ross [11 ]
机构：
[1] Yale Canc Ctr, New Haven, CT USA
[2] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA
[3] Univ Chicago Med, Chicago, IL USA
[4] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] Dexeus Univ Inst, Barcelona, Spain
[7] Catalan Inst Oncol, Barcelona, Spain
[8] Massachusetts Gen Hosp, Boston, MA 02114 USA
[9] Canc Treatment Ctr Amer, Goodyear, AZ USA
[10] Ariad Pharmaceut Inc, Cambridge, MA USA
[11] Univ Colorado, Ctr Canc, Aurora, CO USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
NSCLC; TKI; brigatinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ORAL33.06
引用
收藏
页码：S238 / S239
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of brigatinib (AP26113) in ALK+ NSCLC: phase 1/2 trial results
    Gettinger, S. N.
    Bazhenova, L. A.
    Salgia, R.
    Langer, C. J.
    Gold, K.
    Rosell, R.
    Shaw, A. T.
    Weiss, G. J.
    Dorer, D. J.
    Rivera, V. M.
    Kerstein, D.
    Camidge, D. R.
    LUNG CANCER, 2016, 91 : S20 - S21
  • [2] Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK plus non-small cell lung cancer (NSCLC).
    Camidge, D. Ross
    Bazhenova, Lyudmila
    Salgia, Ravi
    Langer, Corey J.
    Gold, Kathryn A.
    Rosell, Rafael
    Shaw, Alice Tsang
    Weiss, Glen J.
    Narasimhan, Narayana I.
    Dorer, David J.
    Rivera, Victor M.
    Clackson, Timothy Piers
    Conlan, Maureen G.
    Kerstein, David
    Haluska, Frank G.
    Gettinger, Scott N.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Assessment of Brigatinib (AP26113) CNS Activity in Patients (Pts) With ALK plus NSCLC and intracranial metastases in a Phase 1/2 Study
    Camidge, D. R.
    Bazhenova, L. A.
    Salgia, R.
    Langer, C. J.
    Gold, K.
    Rosell, R.
    Shaw, A. T.
    Weiss, G. J.
    Dorer, D. J.
    Rivera, V. M.
    Conlan, M. G.
    Kerstein, D.
    Gettinger, S. N.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S616 - S616
  • [4] Brigatinib in Crizotinib-Refractory ALK plus NSCLC: Updated Efficacy and Safety Results From ALTA, a Randomized Phase 2 Trial
    Ahn, M.
    Camidge, D. R.
    Tiseo, M.
    Reckamp, K.
    Hansen, K.
    Kim, S.
    Huber, R.
    West, H.
    Groen, H.
    Hochmair, M.
    Leighl, N.
    Gettinger, S.
    Langer, C.
    Paz-Ares, L.
    Smit, E.
    Kim, E.
    Reichmann, W.
    Kerstein, D.
    Kim, D.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1755 - S1756
  • [5] Updated efficacy and safety results from ALTA, a randomized phase 2 trial of brigatinib in crizotinib-refractory ALK plus NSCLC
    Hochmair, M.
    Ahn, M-J
    Camidge, D. R.
    Tiseo, M.
    Reckamp, K.
    Hansen, Holmskov K.
    Kim, S-W
    Huber, R.
    West, H.
    Groen, H.
    Leighl, N.
    Gettinger, S.
    Langer, C.
    Paz-Ares Rodriguez, L.
    Smit, E.
    Kim, E.
    Reichmann, W.
    Kerstein, D.
    Kim, D-W
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 271 - 271
  • [6] EVALUATION OF ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITOR BRIGATINIB [AP26113] IN PATIENTS (PTS) WITH ALK plus NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES
    Kerstein, D.
    Gettinger, S.
    Gold, K.
    Langer, C. J.
    Shaw, A. T.
    Bazhenova, L. A.
    Salgia, R.
    Dorer, D. J.
    Conlan, M. G.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2015, 26
  • [7] Updated efficacy and safety of the ALK inhibitor AP26113 in patients (pts) with advanced malignancies, including ALK plus non-small cell lung cancer (NSCLC).
    Gettinger, Scott N.
    Bazhenova, Lyudmila
    Salgia, Ravi
    Langer, Corey J.
    Gold, Kathryn A.
    Rosell, Rafael
    Shaw, Alice Tsang
    Weiss, Glen J.
    Narasimhan, Narayana I.
    Dorer, David J.
    Rivera, Victor M.
    Clackson, Tim
    Haluska, Frank G.
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] ALK INHIBITOR AP26113 IN PATIENTS WITH ADVANCED MALIGNANCIES, INCLUDING ALK plus NON-SMALL CELL LUNG CANCER (NSCLC): UPDATED EFFICACY AND SAFETY DATA
    Gettinger, S.
    Bazhenova, L.
    Salgia, R.
    Langer, C.
    Gold, K.
    Rosell, R.
    Shaw, A.
    Weiss, G. J.
    Narasimhan, N. I.
    Dorer, D. J.
    Rivera, V. M.
    Clackson, T.
    Haluska, F. G.
    Camidge, R.
    ANNALS OF ONCOLOGY, 2014, 25
  • [9] Efficacy and safety of AP26113 in ALK+ non-small cell lung cancer (NSCLC), including patients with brain metastases
    Gettinger, S. N.
    Bazhenova, L.
    Salgia, R.
    Langer, C. J.
    Gold, K. A.
    Rosell, R.
    Shaw, A. T.
    Weiss, G. J.
    Narasimhan, N. I.
    Dorer, D. J.
    Rivera, V. M.
    Clackson, T.
    Haluska, F. G.
    Camidge, D. R.
    LUNG CANCER, 2015, 87 : S32 - S32
  • [10] The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models
    Zhang, Sen
    Anjum, Rana
    Squillace, Rachel
    Nadworny, Sara
    Zhou, Tianjun
    Keats, Jeff
    Ning, Yaoyu
    Wardwell, Scott D.
    Miller, David
    Song, Youngchul
    Eichinger, Lindsey
    Moran, Lauren
    Huang, Wei-Sheng
    Liu, Shuangying
    Zou, Dong
    Wang, Yihan
    Mohemmad, Qurish
    Jang, Hyun Gyung
    Ye, Emily
    Narasimhan, Narayana
    Wang, Frank
    Miret, Juan
    Zhu, Xiaotian
    Clackson, Tim
    Dalgarno, David
    Shakespeare, William C.
    Rivera, Victor M.
    CLINICAL CANCER RESEARCH, 2016, 22 (22) : 5527 - 5538
12345